efaproxiral has been researched along with Benign Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kolman, A | 1 |
| Knox, S; Rosenberg, A | 1 |
| Abraham, DJ; Dusenbery, KE; Gerber, MJ; Kavanagh, BD; Khandelwal, SR; Pearlman, AD; Roberts, JD; Schmidt-Ullrich, RK; Shaw, EG; Venitz, J | 1 |
3 review(s) available for efaproxiral and Benign Neoplasms
| Article | Year |
|---|---|
Efaproxiral (Allos Therapeutics).
Topics: Aniline Compounds; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Contraindications; Humans; Neoplasms; Propionates; Radiation-Sensitizing Agents; Structure-Activity Relationship | 2003 |
Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Topics: Aniline Compounds; Animals; Clinical Trials as Topic; Combined Modality Therapy; Drugs, Investigational; Humans; Neoplasms; Propionates; Radiation-Sensitizing Agents | 2005 |
Radiation sensitization with redox modulators: a promising approach.
Topics: Aniline Compounds; Anthraquinones; Cell Hypoxia; Clinical Trials as Topic; DNA Damage; Drug Approval; Drug Therapy, Combination; Humans; Hypoxia-Inducible Factor 1; Maximum Tolerated Dose; Metalloporphyrins; Neoplasms; Oxidation-Reduction; Propionates; Radiation-Sensitizing Agents; Tirapazamine; Triazines | 2006 |
1 trial(s) available for efaproxiral and Benign Neoplasms
| Article | Year |
|---|---|
A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Cell Hypoxia; Erythrocytes; Female; Hemoglobin A; Humans; Male; Middle Aged; Neoplasms; Oxygen; Partial Pressure; Propionates; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2001 |